✨ Free AI Report
Veru Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Veru Inc.
Company Research

Veru Inc.: Business Overview, Financials & Competitive Analysis

Veru Inc. is a late clinical stage biopharmaceutical company focused on developing novel medicines for treatment of cardiometabolic and inflammatory diseases, with two lead late-stage small molecule drug candidates: e...

Analyst-debate audio for Veru Inc.

AskCyborg analysts argue the bull and bear cases for Veru Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
6/ 10Solid

Cyborg Score thesis

Late-stage obesity-focused biotech with validated clinical strategy and FDA regulatory support, positioned in a multi-hundred...

Read the full analyst-debate transcript →
Industry Biopharmaceutical - Cardiometabolic & Inflammatory Diseases
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Veru Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Veru Inc. Overview

Pro stress-test →

Veru Inc. is a late clinical stage biopharmaceutical company focused on developing novel medicines for treatment of cardiometabolic and inflammatory diseases, with two lead late-stage small molecule drug candidates: enobosarm and sabizabulin. The company is primarily positioned in the rapidly expanding obesity and weight management market through its lead asset enobosarm.

Strategic Profile

Pro stress-test →

Enobosarm is a selective androgen receptor modulator (SARM) being developed as a next generation drug that makes weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass thereby improving body composition and physical function. The company achieved regulatory clarity from the FDA for enobosarm as a muscle preservation drug in combination with GLP-1 RA therapy for obesity, with Phase 2b PLATEAU study planned to start Q1 2026.

Competitive Landscape

Pro stress-test →

Veru focuses on addressing muscle loss in patients undergoing weight loss therapy with GLP-1 drugs, positioning against existing GLP-1 monotherapies. Primary competition comes from large pharma companies (Novo Nordisk, Eli Lilly, Viking Therapeutics) developing obesity treatments, though Veru's muscle-preservation angle offers differentiation in the expanding weight management category.

Industry Context

Veru Inc. operates in Biopharmaceutical - Cardiometabolic & Inflammatory Diseases.

Key facts

Founded: 1971 · Headquarters: Miami, FL · Market cap: ~$300M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Veru Inc..

  • FDA guidance indicates ≥5% placebo-corrected incremental weight loss at 52 weeks or smaller weight difference with clinically meaningful physical function benefit may support approval.
  • Average analyst rating is "Strong Buy" with 12-month stock price target of $22.50, representing 772% upside from recent prices.
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026Q1 fiscal 2026 results and clinical updates announced
  • December 2025FDA regulatory clarity achieved for enobosarm with Phase 2b PLATEAU study planned for Q1 2026
  • +1 moreTrack every material event for Veru Inc. as it happens. Explore monitoring →
Get alerted when Veru Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

SemaglutideGLP-1 receptor agonist for weight management and diabetes→TirzepatideGIP/GLP-1 receptor agonist for weight management→VK2735Dual GLP-1/GCG receptor agonist in development for obesity→

Compare Veru Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Veru Inc. operates in Biopharmaceutical - Cardiometabolic & Inflammatory Diseases. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceutical - Cardiometabolic & Inflammatory Diseases research →
NEW · MCP server

Ask your AI assistant about Veru Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Veru Inc. and its top competitor on Cyborg Score”
“What did Veru Inc. do this quarter?”
“Is Veru Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Veru Inc. do?+
Veru Inc. is a late clinical stage biopharmaceutical company focused on developing novel medicines for treatment of cardiometabolic and inflammatory diseases, with two lead late-stage small molecule drug candidates: e...
What is Veru Inc.'s Cyborg Score?+
Veru Inc. has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Veru Inc.'s main competitors?+
Named competitors include Semaglutide, Tirzepatide, VK2735. The full competitive landscape is in the AskCyborg report.
How can I get the full Veru Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Veru Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Veru Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.